42 results about "Cardiogenic shock" patented technology

The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.

Systems and methods for prediction and detection of circulatory shock using estimates or measurements of arterial blood pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, cardiac ejection fraction, cardiac contractility and ventricular end-diastolic volume are provided. These estimates and measurements are used to determine a type of circulatory shock. In some embodiments, the type of circulatory shock is determined to be one of septic shock, hypovolemic shock, anaphylactic shock, hemorrhagic shock, and cardiogenic shock.

The utility of pulse volume measurement is expanded to detection of many conditions which have previously not been detected or have been detected using more complicated techniques. Such conditions include blood loss, septic shock, cardiogenic shock, neonatal sepsis, patent ductus arteriosus, limb ischemia, intra-aortic balloon pump performance, peripheral vascular disease, congestive heart failure, the effectiveness of vasoactive medications, syncope, dehydration, pre-eclampsia, deep vein thrombosis, thermal injuries, vascular instability due to renal dialysis, compromising of circulation to the hand caused by radial artery harvesting, changes in cardiac output, and hypertension. According to the present invention, such diagnoses can be performed by taking one measurement, by taking measurements over time to detect a change or by taking measurements before and after application of a treatment or stimulus.

The invention belongs to the field of medical apparatuses, and relates to an artificial heart assisting device for treating heart failure caused by acute cardiogenic shock, in particular to an in-vitro non-implantable maglev heart chamber assisting centrifugal blood pump. The in-vitro non-implantable maglev heart chamber assisting centrifugal blood pump adopts a non-bearing magnetic fluid levitation technology to substitute mechanical bearing driving of the conventional centrifugal blood pump, an impeller rotor is suspended in a magnetic field without any mechanical contact, and the position and the speed of the impeller rotor are precisely regulated by a digital signal processor system, so that damage to blood cells and visible components (platelets, blood coagulation factors and the like) of blood is reduced to the most extent; meanwhile, by a heparin coating technology applicable to the inner wall of the blood pump and the surface of the impeller rotor, coagulation and thrombosis as well as use of an anticoagulant medicine in the assisting process are further reduced, so that complications of hemorrhage of a patient during a surgery are reduced. The in-vitro non-implantable maglev heart chamber assisting centrifugal blood pump has the characteristics of being simple in structure, reliable in operation, convenient to maintain, stepless in speed regulation and the like, can be used for treating the heart failure caused by acute cardiogenic shock triggered by a variety of reasons, and in combination with an oxygenator, can also be used for assisting circulation and blood oxygenation during extracorporeal membrane oxygenation (ECMO) treatment.

The present invention provides a method and device for non-invasive anatomical and systemic cooling, fluid removal and / or energy removal. The present invention provides for removal of fluid and cooling of various bodily fluid-containing spaces or surfaces, such as mucus-containing spaces or surfaces via delivery of a dry fluid not including a coolant into or upon the mucus-containing space or surface. Exposure of mucus to the dry fluid yields evaporation of body fluid, removal of energy, cooling of the anatomical feature, and systemic cooling. Therefore, therapeutic hypothermia may be achieved for neuroprotection of various organs after ischemic insult, like the brain after cardiac arrest. Similarly, excess fluid removal is achievable for treatment of cardiogenic shock or other conditions that cause significant fluid build-up, especially in cases of compromised renal function. Additionally, the invention may be used to reduce fever, and other conditions where removal of heat, energy and / or water are beneficial.

The invention relates to a hydroxypropyl-beta-cyclodextrin inclusion compound of ginseng essential oil, a preparation method and application. The ginseng essential oil is a liposoluble constituent indissoluble in water, and is generally applied to ginsenoside preparations in clinics. The hydroxypropyl-beta-cyclodextrin inclusion compound of the invention is prepared from the following ingredients in percentage by weight: 1 of ginseng essential oil and 1 to 100 of hydroxypropyl-beta-cyclodextrin. The ginseng essential oil is added into a water solution containing the hydroxypropyl-beta-cyclodextrin, the ultrasonic treatment is carried out at 30 DEG C at 40 KHz, and then, water-soluble inclusion compounds are formed through being dried. The hydroxypropyl-beta-cyclodextrin inclusion compound can be used as ingredients of medicine for treating body deficiency and prostration, faint pulse and cold extremities, spleen deficiency and poor appetite, pulmonasthenia cough, body fluid deficiency and thirst, internal heat thirst, macronosia deficiency, cardiac shock and the like.

The invention discloses a pharmaceutical composition, its preparing process and use, wherein the composition comprises red ginseng extract and ophiopogon root extract by a predetermined proportion, and can be used for treating cardiogenic shock and hemorrhagic shock.

The invention belongs to traditional Chinese medicine preparation and the technical field of the production method thereof. A pulse callbladder-warming decoction new dosage type applies the modernized traditional Chinese medicine theory and the new process, the new technology and the new equipment produced by the traditional Chinese medicine preparation to develop a pulse callbladder-warming decoction new does type peroral traditional Chinese medicine preparation which can fully realize the characteristic of the traditional Chinese medicine preparation and can effectively control the product quality on the basis of the dosage type of the pulse callbladder-warming decoction preparation of the traditional preparation, particularly, the pulse callbladder-warming decoction new dosage type adopts 11 components of traditional Chinese medicine such as pinellia tuber, fresh ginger, bamboo shavings, immature bitter orange, tangerine peel, licorice root, indian bread, Chinese date, ginseng, ophiopogon root and magnolia vine fruit as main raw material to develop a new product of the pulse callbladder-warming decoction new does type traditional Chinese medicine preparation which has the function of supplementing qi and nourishing yin, and removing dampness and resolving heat and is used for pathological symptoms such as coronary heart disease and ventricular extrasystole is developed. The pulse callbladder-warming decoction new does type keeps the inherent characteristic of the original medical broth, has the advantages that the dosage for taking is small, the taking is easy, the dosage is accurate, and the quality is stable, and is suitable for the big production of the mechanization. The invention overcomes the defects that the dosage of the pulse callbladder-warming decoction new does type is big, the carrying is not convenient, the storage can not be long, and the mechanizing production can not be performed.

The invention relates to a novel stable protein kinase activator adenosine cyclophosphate salt derivate, which has high storage stability and preparation performance and can be used in the preparation of medicaments for treating or preventing the following human and animal diseases such as stenocardia, cardiac failure, myocardial infarction, myocarditis, arrhythmia, cardiogenicshock, acute leukemia, nerve system diseases, respiratory system diseases, senile chronic bronchitis, hepatitis, psoriasis and the like and relieving the symptoms, such as cardiopalmus, shortness of breath, chest distress and the like of rheumatic heart disease.

The invention discloses a pharmaceutical composition of ginseng and monkshood, wherein the content of monkshood alkaloid is not lower than 50%. The pharmaceutical composition provided by the invention has the advantages of controllable quality, better stability, and improved pharmacological actions. The monkshood alkaloid extract is prepared through specially treating monkshood, hydrolyzing di-ester aconitine in monkshood so as to convert it into low-toxicity alkaloid. The obtained composition can be used for treating infectious shock, bleeding shock and cardiogenic shock.

A freeze-dried powder injection of VC for preventing and treating scurvy, acute and chronic infectious diseases, purpura, Keshan disease, etc is prepared from VC, sodium hydrogen sulfate, and disodium versenate through ultrasonic treating, adding CO2 saturated water for injection in dark condition and N2 atmosphere, regulating pH value and temp, etc.

The invention relates to a traditional Chinese medicinal injection for treating coronary disease, climacteric metancholia, myocardial ischemia, hypoxic encephalopathy and hyperlipoidemia. The invention also discloses its preparing process, new route of administration and new indication errors. The injection is prepared from total saponins of ginseng leaves as raw material, as well as concentrated solution for injection, freeze-dried powder, 5% glucose and 0.9% sodium chloride.

The invention relates to the use of penehyclidine hydrochloride in the preparation of medicines for treating cardiogenic shock diseases indicating that, in pathological changes, systolic pressure and mean arterial pressure decrease at least by 40%, the maximum rise speed of internal pressure of left ventricle (LV+dp / dtmax) decreases at least 80%, cardiac output decreases at least 40%. The application effect of the invention is shown by the influence of the penehyclidine hydrochloride on acute cardiogenic shock modles.

The invention relates to inhibitors of Multi drug Resistant Protein 4 (MRP4) for the treatment and / or the prevention of cardiac disorders, such as acute or chronic heart failure and cardiogenic shock. The invention also relates to agents stimulating MRP4 activity for the treatment and / or the prevention of cardiac hypertrophy.

The present invention provides a method and device for non-invasive anatomical and systemic cooling, fluid removal and / or energy removal. The present invention provides for removal of fluid and cooling of various bodily fluid-containing spaces or surfaces, such as mucus-containing spaces or surfaces via delivery of a dry fluid not including a coolant into or upon the mucus-containing space or surface. Exposure of mucus to the dry fluid yields evaporation of body fluid, removal of energy, cooling of the anatomical feature, and systemic cooling. Therefore, therapeutic hypothermia may be achieved for neuroprotection of various organs after ischemic insult, like the brain after cardiac arrest. Similarly, excess fluid removal is achievable for treatment of cardiogenic shock or other conditions that cause significant fluid build-up, especially in cases of compromised renal function. Additionally, the invention may be used to reduce fever, and other conditions where removal of heat, energy and / or water are beneficial.

The relates to the application of panaxadiol saponin in preparing anti-shock medicine, and belongs to the field of new use of effective Chinese medicine components. The present invention aims at applying panaxadiol saponin in preparing medicine for resisting cardiac shock. The present invention has the features of less side effect and high curative effect, and is superior to available anti-shock Western medicines, such as dexamethasone.

Methods of reducing sepsis or cardiogenic shock in patients experiencing myocardial injury are described. More specifically, this disclosure relates to the administration of a C5-C9 terminal complement inhibitor to patients who have had coronary artery bypass grafting or an acute myocardial infarction thereby reducing the incidence of sepsis.

The invention relates to a metabonomics analysis method based on a cardiac shock rat model. The method comprises the following steps of: copying early and middle cardiac shock rat models by adopting a left anterior descending coronary branch proximal tip and telecentric tip ligation method; acquiring metabolic map information of early-stage and middle-stage plasma samples of cardiac shock of rats on the basis of an ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometer; and performing data preprocessing by using Progenense QI, performing multivariate statistical analysis by using EZinfo 2.0 statistical software, screening out a biomarker group with significant difference, analyzing a metabolic pathway in which the biomarker group participates through a Metaboanist.ca website, and discussing an action mechanism of treating early and middle stages of cardiac shock by using the ginseng-radix aconiti carmichaeli injection. According to the invention, the influence and change rule of external stimulation on the endogenous micromolecules of the living body are researched from the overall perspective, and a new research thought and method are provided for the research on the syndromes of traditional Chinese medicine and the overall action mechanism of the traditional Chinese medicine.

The present invention relates to compositions and methods of use thereof for treatment of clinical conditions manifested from and / or exacerbated by a decrease or an inhibition of Na / K ATPase activity. The invention relates to composition comprises monoclonal or polyclonal antibodies to bufalin and / or bufalin sulfate, or vaccination against bufalin and / or bufalin sulfate, which prevents or attenuates inhibition of Na / K ATPase activity thereby attenuating the adverse physiological effects of bufalin and / or bufalin sulfate inhibition. The invention also relates to methods of treating hemorrhagic, septic shock, cardiogenic shock, shock resulting from physical trauma, diabetes, mental depression, bipolar disorder and schizophrenia comprising administering a therapeutically effective amount of an bufalin monoclonal or polyclonal antibody.

The invention discloses a medicine composition for treating cardiac and pulmonary multi-viscera failure, which is prepared from 27 types of medicines, such as unprocessed radix aconiti lateralis, honey monkshood, rhizoma zingiberis, radix glycyrrhizae preparata, ginseng, fructus corni and the like. On the aspect of compatibility of medicines, a medicine boiling method is improved. Honey is added into the whole medicine to be mutually boiled, and a long boiling method keeps constant effect, is safe and stable and does not have risks. The medicine composition has an obvious curative effect on circulation failure caused cardiogenic shock, toxic shock, atrophic lung disease, gurgling sound of phlegm in the throat, hemorrhagic shock and emergency, can prevent typhoid fever, common cold and flu, and has the efficacy of delaying the ageing speed of viscera, nourishing yin, tonifying Yang, improving immunity, soothing the liver and relieving depression.

The invention relates to applications of a histone deacetylase inhibitor in preparing an antishock drug, especially applications of S-(E)-3-[1-(1-benzo[d]oxazole-2-yl)-2-methylpropyl]-1H-1,2,3-triazole-4-yl]-N-Methylol acrylamide as shown in the specification in preparing the antishock drug, the shock is preferably selected from traumatic shock, hypovolemic shock, infectious shock, neurogenic shock, cardiogenic shock and anaphylactic shock, especially burning shock preferably.

The present invention discloses a method of enhancing cardiac contractility in a subject with heart failure. The method consists of administering a compound that inhibits the sarcolemmal sodium / calcium exchanger, whose activity is elevated in heart failure. This method results in correction of cellular calcium handling and enhancement of cardiac contractility to healthy levels. This method can be used for treatment of acute heart failure, cardiogenic shock and congestive heart failure.

The invention relates to inhibitors of Multi drug Resistant Protein 4 (MRP4) for the treatment and / or the prevention of cardiac disorders, such as acute or chronic heart failure and cardiogenic shock. The invention also relates to agents stimulating MRP4 activity for the treatment and / or the prevention of cardiac hypertrophy.